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Cooperative Planning Grant for Cancer Disparities
Research Partnership Program
The National Cancer Institute (NCI) invites coopera-
tive planning grant applications to develop models to
reduce significant negative consequences of cancer dis-
parities seen in certain U.S. populations. This grant
will support the planning, development, and conduct
of radiation oncology clinical research trials in institu-
tions that care for a disproportionate number of med-
ically underserved, low-income, ethnic, and minority
populations but have not traditionally been involved in
NCI-sponsored research. The grant will also support
the planning, development, and implementation of
nurturing partnerships between applicant institutions
and committed, experienced institutions actively
involved in NCI-sponsored cancer research. 
The NCI is strongly committed to reducing can-
cer-related health disparities across the cancer control
continuum from prevention to end of life. The NCI
supports research to understand the complex causes of
disparities in cancer risk, incidence, and mortality,
including socioeconomic, cultural, environmental,
institutional, behavioral, biological, and other con-
tributing factors seen in the health care delivery system.
The overall goal is to understand the causes of health
disparities and to develop effective interventions to
eliminate these disparities that result in significant neg-
ative outcomes.
The populations targeted by this cooperative plan-
ning grant tend to access the health care system in the
advanced stages of their disease. Because of this, radia-
tion oncology usually represents a major treatment
alternative. Therefore, the field of radiation oncology
offers a unique opportunity to explore ways to reduce
the significant negative consequences of cancer-related
health disparities. 
Institutions, with the necessary resources, mentor-
ing, and supportive partnership with an experienced
and committed research institution, represent an
opportunity for conducting and expanding participa-
tion in clinical trials developed for radiation oncology
and combined modality therapy as well as culturally
and societally related research important to the under-
standing of cancer-related health disparities. However,
health care institutions providing cancer services to a
disproportionate number of medically underserved,
low-income, and/or minority populations, whether
urban or rural, often are not linked to the national can-
cer research enterprise as effectively as they could be
and often struggle to maintain state-of-the-art cancer
care. Radiation oncologists in these institutions have
difficulty starting, developing, and sustaining research
programs either independently or collaboratively.
Thus, the populations primarily served by these institu-
tions do not readily benefit from the rapid progress
being made in cancer research in radiation oncology,
and may bear an unequal burden of disease as a result. 
It is necessary to address the low involvement in
cancer research of health care institutions predomi-
nantly serving populations who experience the worst
consequences of cancer-related health disparities. The
increased involvement of these institutions is needed to
develop a stronger national cancer research effort
aimed at understanding the disparities of cancer inci-
dence and mortality in those populations. This cooper-
ative planning effort is dedicated to developing stable,
long-term radiation oncology clinical research trials,
programs, and partnerships to increase the participa-
tion of applicant institutions in the nation’s cancer
research enterprise.
The four overall objectives and scope of this RFA
are to solicit cooperative planning grants that 1) build
and stabilize independent and collaborative clinical
research capabilities of institutions providing radiation
oncology care to populations experiencing the negative
consequences of cancer-related health disparities; 2)
increase the number of clinical scientists engaged in
radiation oncology research by providing access to and
participation in clinical trials with the target popula-
tions; 3) improve the effectiveness of the applicant
institution and its partner institution in developing and
sustaining activities focused on radiation oncology clin-
ical research trials and mortality and morbidity in can-
cer among the target populations, continuing past the
life of this grant; and 4) establish priorities for and ini-
tiate stable, long-term collaborations and partnerships
that will strengthen competitive cancer research,
research training and career development, education,
and outreach capabilities at both the applicant institu-
tion and the partner institution that address problems
and issues relevant to the disproportionate cancer inci-
dence and mortality. 
All approaches to planning are encouraged, as
long as they address the following essential features: a
focus on cancer disparities, radiation oncology clinical
research, institutional commitment, organizational
capabilities, facilities, and interdisciplinary coordina-
tion and collaboration. 
The NCI plans to commit approximately $2.8
million in direct costs in fiscal year 2003 to fund up to
four new grants in response to this RFA. Applicants
may request a project period of up to five years and an
annual budget for direct costs of up to $400,000 per
year over five years, excluding one-time capital costs
expended in the first year. Awards pursuant to this
RFA are contingent upon the availability of funds and
the receipt of a sufficient number of meritorious appli-
cations. The total project period for applications sub-
mitted may not exceed five years. The anticipated
award date is 20 September 2003.
Applications will only be accepted from health
care institutions accredited by the Joint Commission
on Accreditation of Health Organizations or free-
standing cancer centers accredited by a nationally rec-
ognized accrediting body such as the American
College of Radiology (either in the United States or in
territories under U.S. jurisdiction) that have letters of
commitment from potential partners that are NCI-
designated cancer centers, RTOG-participating insti-
tutions, or other NCI-sponsored cooperative group
participating institutions wishing to develop compre-
hensive partnerships with the applicant institution. 
Applications must be prepared using the PHS 398
grant application instructions and forms (rev. 5/2001).
The PHS 398 is available at http://grants.nih.gov/
grants/funding/phs398/phs398.html in an interactive
format. The deadline for letters of intent is 20
February 2003, with final applications due 20 March
2003. More information on this RFA is available
online at http://grants1.nih.gov/grants/guide/
rfa-files/RFA-CA-03-018.html. 
Contact: Frank Govern, Radiation Oncology
Sciences Program, NCI, Executive Plaza North,
6015A, 6130 Executive Boulevard, MSC 7440,
Bethesda, MD 20892-7440 USA, 301-496-6111, fax:
301-480-5785, e-mail: governfr@mail.nih.gov;
Norman Coleman, Radiation Oncology Sciences
Program, NCI, DCTD, RRP, Executive Plaza North,
6015A, 6130 Executive Boulevard, MSC 7440,
Bethesda, MD 20892-7440 USA, 301-496-6111, fax:
301-480-5785, e-mail: ccoleman@mail.nih.gov.
Reference: RFA No. RFA-CA-03-018
Continued Development and Maintenance of
Bioinformatics/Computational Biology Software 
Biomedical research laboratories occasionally create
software to solve a problem the laboratory faces. These
software packages sometimes evolve into a well-
designed system that can be easily extended and that is
useful to a much broader community beyond the
members of the originating laboratory. The goal of this
PA is to support the continued development, mainte-
nance, testing, and evaluation of existing software. The
proposed work should apply best practices and proven
methods for software design, construction, and imple-
mentation to extend the applicability of existing bioin-
formatics/computational biology software to a broader
biomedical research community.
This initiative pertains to bioinformatics/compu-
tational biology software that is recognized to perform
an important function in furthering biomedical
research. The software should perform reliably and pre-
cisely according to the computing demands of end
users. The algorithms that are employed by the soft-
ware should be well documented, as should be the
underlying assumptions of these algorithms to prevent
potential misuse.
Contemporary software must be fully document-
ed and easy to modify and extend. Defects that arise in
any software must be correctable with limited effort. As
the needs of a community of users change, the software
that supports their research efforts must be easily modi-
fied. Reparability and evolvability are particularly
important because the scientific discovery process is
open-ended and ever-changing. Interoperability and
portability are also a major concern. Where appropri-
ate, software applications should operate on a variety of
platforms employing different operating systems. 
Awards made under this PA will support contin-
ued software development, evaluation, and testing of
preexisting bioinformatics/computational biology soft-
ware for data management and analysis, computational
biology, and modeling and simulation. Support will be
provided for porting software to new platforms and
operating systems as well as the costs associated with
maintaining the software as existing operating systems
change. The proposed software should not substantial-
ly duplicate another software package that is already in
wide use.
This PA will use the NIH R01 award mecha-
nism as well as competitive supplements to existing
R01, R33, P01, P41, P50, and P60 grants that have
already been awarded by one of the participating
institutes or centers. Applications for competitive
supplements cannot extend beyond the parent pro-
ject period of performance, and the principal investi-
gator must be the same.
Applications must be prepared using the PHS 398
research grant application instructions and forms (rev.
5/2001). The PHS 398 is available at http://grants.nih.
gov/grants/funding/phs398/phs398.html in an interac-
tive format. Applications submitted in response to this
PA will be accepted at the standard application dead-
lines, available at http://grants.nih.gov/grants/
dates.htm. Application deadlines are also indicated in
the PHS 398 application kit.
Contact: Bret Peterson, NCRR, One Rockledge
Centre, Room 6152, 6705 Rockledge Drive, MSC
7965, Bethesda, MD 20892-7965 USA, 301-435-
0758, fax: 301-480-3659, e-mail: bretp@
ncrr.nih.gov; Yuan Liu, NINDS, Neuroscience
Building, Room 2110, 6001 Executive Boulevard,
MSC 9523, Bethesda, MD 20892-9523 USA, 301-
496-1917, fax: 301-480-2424, e-mail: liuyuan2@
ninds.nih.gov; Karen Skinner, Division of
Neuroscience and Behavior Research, NIDA, Room
4255, 6001 Executive Boulevard, Bethesda, MD
20892-9651 USA, 301-435-0886, fax: 301-594-
6043, e-mail: ks79x@nih.gov; Michael Huerta,
Division of Neuroscience and Basic Behavioral
Science, NIMH, 6001 Executive Boulevard, Room
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7202, MSC 9645, Bethesda, MD 20892-9645 USA,
301-443-3563, fax: 301-443-1731, e-mail: mhuerta@
helix.nih.gov; James Cassatt, Division of Cell
Biology and Biophysics, NIGMS, 45 Center Drive,
MSC 6200, Bethesda, MD 20892-6200 USA, 301-
594-0828, fax: 301-480-2004, e-mail: cassattj@
nigms.nih.gov; Richard E. Swaja, NIBIB, 6707
Democracy Boulevard, Suite 900, Bethesda, MD
20892-5469 USA, 301-451-4779, fax: 301-480-
4973, e-mail: swajar@nibib.nih.gov; Carol Bean,
Extramural Programs, NLM, One Rockledge
Centre, Suite 301, 6705 Rockledge Drive, Bethesda,
MD 20892 USA, 301-594-4882, fax: 301-402-
2952, e-mail: cb389x@nih.gov; Peter Good,
NHGRI, Building 31, Room B2B07, Bethesda, MD
20892-2033 USA, 301-435-5796, fax: 301-480-
2770, e-mail: Peter_Good@nih.gov; Ellen
Liberman, NEI, Executive Plaza South, Suite 350,
6120 Executive Boulevard, MSC 7164, Bethesda,
MD 20892-7164 USA, 301-451-2020, fax: 301-
502-0528, e-mail: ellenliberman@nei.nih.gov;
Antonio Norhona, NIAAA, 6000 Executive
Boulevard, Bethesda, MD 20892-7003 USA, 301-
443-7722, fax: 301-594-0673, e-mail: anoronha@
willco.niaaa.nih.gov. Reference: PA No. PA-02-141
Genetic Architecture, Biological Variation, and
Complex Phenotypes
This PA updates PA-98-078, “Genetic Architecture
of Complex Phenotypes.” The purpose of this PA is
to solicit applications for new studies on genetic
variation and the architecture of complex pheno-
types. It restates the interest of several components
of the NIH in studies of the underlying causes and
architecture of complex phenotypes, including
human diseases. It is motivated by the amount and
complexity of biological data that are being gener-
ated and by the understanding that complex phe-
notypes involve many genetic components that
evolve in a variety of environments. 
Complex phenotypes are those that exhibit
familial clustering, which may mean that there is
some genetic component, but that do not occur in
Mendelian proportions in pedigrees. Complex phe-
notypes may be continuous in distribution (e.g.,
height or blood pressure), or they may be dichoto-
mous (e.g., affected and not affected). The complexi-
ty arises from the fact that one cannot accurately
predict the expression of the phenotype from knowl-
edge of the individual effects of individual factors
considered alone, no matter how well understood
each separate component may be. 
The past few decades of biological research
using largely a reductionist approach have yielded
vast amounts of data. In addition, genome
sequencing projects, as well as structural and func-
tional genomics initiatives, are producing data far
more rapidly than scientists can analyze them and
understand their implications to biology and to
health. As overwhelming as the current data are,
they are only the beginning. Protein structures,
DNA sequences, and gene expression patterns vary
among individuals, among species, among popula-
tions within a species, and across environments. It
will soon be possible to utilize information on
thousands of variable genetic sites to investigate
the relationships among genotypes, phenotypes,
and environments. 
The term genetic architecture refers to the full
range of genetic effects on a trait; however, when
studying variation on such a large scale, it is espe-
cially important to consider the context or environ-
ments in which genetic variation arises, is selected,
and is maintained. Genetic architecture is less a
fixed property of the phenotype than a characteristic
of a phenotype in a particular population. Genetic
architecture is a moving target that changes accord-
ing to gene and genotype frequencies, distributions
of environmental factors, and such biological prop-
erties as age and sex. 
Studies of variation or genetic architecture may
employ a variety of conceptual approaches. A
researcher may consider the combinatorial effects of
many variable sites, whether the scale is within a gene
or across a genome. Comparative genomics, where
the goal is to identify patterns of variation among
genomes, is also a productive way of identifying
attributes of variation, such as which genomic regions
are rapidly evolving. Another approach is to study
variation related to biological levels of organization,
such as DNA sequence, protein structure, metabolic
pathways, cell dynamics, individual phenotype, and
population characteristics. The following are typical
of research areas targeted by this initiative: 
Biological variation: Studies of genetic archi-
tecture have historically focused on associations of
genotype and phenotype (e.g., between DNA
markers and a disease). However, an organism is a
unique consequence of both genes and environ-
ment and is created by complex interactions of
multiple events and forces. How genes are
expressed depends on their cellular, developmental,
physiological, and environmental context. This ini-
tiative encourages research on biological variation
and interactions such as 1) variation in basic bio-
logical systems, including sequences, structures,
and pathways that direct metabolism and develop-
ment; 2) variation in these systems within individu-
als, among individuals, among populations, and
among species with the goal of learning how these
complex systems interact and evolve; 3) determina-
tion of the extent to which genetic architecture is
shared across populations and among species; 4)
effects of admixture, population history, recombi-
nation, mutation, population structure, selection,
and drift on the organization of variation; 5) collec-
tion and analysis of both new and existing data; 6)
tools and models for identifying and measuring
important contextual features; and 7) measuring
the impact of context on biological data. 
Evolution of genome properties: An emerging
area of research focuses on how properties of
genomes arise in evolutionary history. Such
research has important consequences for under-
standing genome organization and for interpreting
data on genetic and phenotypic variation. Such
research could include the evolution of haplotypes,
selection for genetic interactions, and the evolution
of recombination and methylation patterns. 
Extensions to other organisms: Many organ-
isms have been studied for their value in agriculture
or ecology. Thus, there is considerable information
about the population structure, natural history, and
genetics of these systems. It will be valuable to take
advantage of this wealth of information to study
variation in the natural settings in which it evolved.
Bioinformatics: The study of biological varia-
tion depends heavily on rich data sets; researchers
need the ability to access many kinds of information
(e.g., DNA sequence, protein structure, develop-
ment, natural history, and phenotype) in organisms
from different habitats, from different populations,
and from different species. This initiative supports
development of tools to help researchers use data
from many databases to address research questions. 
Improved dynamic modeling and statistical
methods: Mathematical approaches to studying
biological variation have changed little in several
decades. There is a need to develop new dynamic
models to illuminate how systems interact and
evolve. Just as important, it is critical to study the
nature of biological and mathematical assumptions
of models and statistics. Tools for analyzing and
interpreting data on the architecture of complex
phenotypes should be developed in the context of
real biological information. Areas of particular
interest for this initiative include 1) implications
and appropriate uses of different sampling strate-
gies; 2) analytical tools to discover patterns of
genotypic variation and their roles in conferring
phenotype; 3) incorporation of data from new
technologies; 4) development of robust methods
that are compatible with real data (missing or
incomplete data, typing errors, experimental
errors); and 5) development of mathematical mod-
els based on empirical information, which includes
such biological realities as epistasis, recombination,
mutation, protein structure, cell biology, metabolic
pathways, development, population history, and
evolution.
Applications submitted in response to this PA
will be accepted at the standard application dead-
lines, available at http://grants.nih.gov/grants/
dates.htm. Complete information on this PA is
available at http://grants1.nih.gov/grants/guide/
pa-files/PA-02-110.html. Applications must be
prepared using the PHS 398 research grant appli-
cation instructions and forms (rev. 5/2001), avail-
able at http://grants.nih.gov/grants/funding/
phs398/phs398.html in an interactive format. 
Contact: Irene Anne Eckstrand, Division of
Genetics and Developmental Biology, NIGMS, 45
Center Drive, MSC 6200, Bethesda, MD 20892-
6200 USA, 301-594-0943, fax: 301-480-2228, e-
mail: Irene_Eckstrand@nih.gov; Lisa Brooks,
NHGRI, 31 Center Drive, 31/B2B07, Bethesda,
MD 20892-2033 USA, 301-435-5544, fax: 301-
480-2770, e-mail: lisa_brooks@nih.gov; Winifred
Rossi, Genetic Epidemiology and Translational
Research, NIA, 7201 Wisconsin Avenue, Suite
3E327, Bethesda, MD 20892-9205 USA, 301-
496-3836, fax: 301-402-1784, e-mail: wr33a@
nih.gov; Lisa Neuhold, Division of Basic
Research, NIAAA, 6000 Executive Boulevard,
Suite 402, Bethesda, MD 20892-7003 USA, 301-
594-6228, fax: 301-594-0673, e-mail: lneuhold@
willco.niaaa.nih.gov; Steven Moldin, Genetics
Research Branch, Division of Neuroscience &
Basic Behavioral Science, NIMH, 6001 Executive
Boulevard, Room 7189, MSC 9643, Bethesda,
MD 20892-9643 USA, 301-443-2037, fax: 301-
443-9890, e-mail: smoldin@mail.nih.gov; Robert
Karp, Division of Digestive Diseases and
Nutrition, NIDDK, 6707 Democracy Boulevard,
Room 671, MSC 5450, Bethesda, MD 20892-
5450 USA, 301-451-8875, fax: 301-480-8300, e-
mail: karpr@extra.niddk.nih.gov; Jonathan
Pollock, Genetics and Molecular Neurobiology
Research Branch, NIDA, 6001 Executive
Boulevard, Room 4274, Bethesda, MD 20892
USA, 301-435-1309, fax: 301-594-6043, e-mail:
jp183r@nih.gov; Jose Velazquez, Division of
Extramural Research and Training, NIEHS, 111
Alexander Drive, Research Triangle Park, NC
27709 USA, 919-541-4998, fax: 919-316-4606,
e-mail: velazqu1@niehs.nih.gov; or Katrina
Gwinn-Hardy, NINDS, 6100 Executive
Boulevard, Room 2142, MSC 9525, Bethesda,
MD 20892 USA, 301-496-5745, fax: 301-402-
1501, e-mail: gwinnk@ninds.nih.gov. Reference:
PA No. PA-02-110
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